Cervical cancer is the second most common malignant tumor in women and the first in China. In recent years, the incidence is gradually becoming younger and the incidence and mortality rate are on the rise. With the introduction of universal HPV testing for cervical cancer screening and HPV vaccine, cervical cancer is expected to become a preventable malignancy. The treatment of cervical cancer emphasizes comprehensive treatment, which is based on treatment guidelines, combined with the specific conditions of patients, and the rational application of multiple treatment means such as surgery, radiotherapy and chemotherapy in a planned and orderly manner. Currently, FIGO and NCCN guidelines are widely used in clinical practice. In the treatment of cervical cancer, surgery and radiotherapy occupy a dominant position. For early-stage cervical cancer patients (I-IIA), both radical surgery alone and radical radiotherapy alone have comparable therapeutic effects, and for those with poor prognostic factors, postoperative adjuvant therapy is required after surgery; for mid- to late-stage cervical cancer above IIB, the recognized preferred method is simultaneous radiotherapy and chemotherapy. Previous chemotherapy is mainly used in the palliative treatment of advanced recurrent refractory cervical cancer. The continuous discovery of new chemotherapeutic agents in the last two decades has gradually converted chemotherapy as a tool in the treatment of cervical cancer. Chemotherapy can be used for preoperative and pre-radiotherapy neoadjuvant chemotherapy, postoperative chemotherapy, concurrent radiotherapy, postoperative concurrent radiotherapy followed by consolidation chemotherapy and palliative chemotherapy for recurrent cancer, but the efficacy of these chemotherapies is inconsistent and some are highly controversial. With the advancement of surgery and precise radiotherapy technology, the local control rate of tumor has improved significantly, and some studies have shown that the local control rate of extracorporeal intensity-modulated radiotherapy combined with three-dimensional rear-loading brachytherapy can reach 70-96%; while the rate of distant metastasis among recurrent patients exceeds 40%. Attention should be paid to the control of distant metastasis in patients with locally advanced cervical cancer. The main treatments for cervical cancer include surgery or radiotherapy. Cisplatin-based concurrent chemotherapy and palliative chemotherapy are important as adjuvant treatments, and the significance of consolidation chemotherapy and neoadjuvant chemotherapy needs to be verified by further studies, and bevacizumab-targeted therapy combined with chemotherapy can be beneficial.